Form 4: Chemours Director Mary Cranston Increases Equity Stake

Director Mary Cranston acquired 7,182 shares of Chemours common stock, bringing her total beneficial ownership to 106,830.0129 shares.

Summary

• Director Mary Cranston acquired 7,182 shares of Chemours (CC) common stock on May 6, 2026.
• The acquisition was granted at a price of $0, typically representing equity compensation for board service.
• Total beneficial ownership following the transaction is 106,830.0129 shares.
• The filing includes an adjustment to total holdings to correct an administrative error in previous filings.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation and a minor correction of previous records, having no material impact on the company's financial outlook.

Positives

• Director maintains a significant equity stake in the company, aligning interests with shareholders.
• Correction of administrative errors ensures transparency and accuracy in reporting.

Negatives

• Administrative error in prior filings indicates a need for improved internal reporting oversight.

Risks

• Reliance on administrative accuracy for regulatory compliance.

Future Outlook

No specific forward-looking guidance provided in this ownership disclosure.

Industry Context

StockSavvy.ai notes that director equity acquisitions are standard practice for board compensation and generally signal confidence in the company's long-term governance and strategic direction.

Comparison to Industry Standards

• The acquisition of equity as part of director compensation is consistent with standard corporate governance practices for S&P 500 companies.

Stakeholder Impact

• Shareholders benefit from increased transparency regarding director equity holdings.

Next Steps

• Continued monitoring of insider transactions for potential shifts in sentiment.

Key Dates

Keywords

Chemours, CC, Insider Trading, Form 4, Director, Equity Compensation